After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback